Zacks: Analysts Anticipate Imperva Inc (IMPV) Will Post Quarterly Sales of $74.29 Million
Equities analysts expect that Imperva Inc (NYSE:IMPV) will post sales of $74.29 million for the current quarter, Zacks reports. Six analysts have provided estimates for Imperva’s earnings, with estimates ranging from $74.09 million to $74.65 million. Imperva posted sales of $57.87 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 28.4%. The business is expected to issue its next earnings results after the market closes on Thursday, July 27th.
On average, analysts expect that Imperva will report full year sales of $74.29 million for the current financial year, with estimates ranging from $320.00 million to $322.90 million. For the next financial year, analysts forecast that the company will report sales of $380.66 million per share, with estimates ranging from $369.00 million to $388.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Imperva.
Imperva (NYSE:IMPV) last released its quarterly earnings data on Thursday, May 4th. The software maker reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.33. Imperva had a net margin of 31.92% and a return on equity of 36.67%. The company had revenue of $72.31 million during the quarter, compared to analyst estimates of $68.16 million. During the same quarter in the prior year, the business earned ($0.25) earnings per share. The business’s quarterly revenue was up 21.0% compared to the same quarter last year.
IMPV has been the topic of several recent research reports. Evercore ISI reiterated a “buy” rating and set a $56.00 price objective on shares of Imperva in a research report on Monday, May 15th. Susquehanna Bancshares Inc initiated coverage on Imperva in a research report on Wednesday, June 7th. They set a “positive” rating and a $60.00 price objective on the stock. TheStreet upgraded Imperva from a “d” rating to a “c” rating in a research report on Thursday, May 4th. BidaskClub lowered Imperva from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 5th. Finally, Zacks Investment Research lowered Imperva from a “buy” rating to a “hold” rating in a research report on Tuesday, May 9th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $50.29.
Imperva (NYSE:IMPV) traded down 2.38% during midday trading on Friday, hitting $49.30. 398,770 shares of the stock traded hands. The firm’s market cap is $1.65 billion. Imperva has a 1-year low of $34.40 and a 1-year high of $57.24. The company has a 50-day moving average price of $49.32 and a 200-day moving average price of $44.70.
In other Imperva news, CRO Michael D. Mooney sold 52,356 shares of the stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $47.51, for a total value of $2,487,433.56. Following the completion of the sale, the executive now owns 52,356 shares in the company, valued at approximately $2,487,433.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Amichai Shulman sold 3,089 shares of the stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $48.70, for a total value of $150,434.30. Following the completion of the sale, the insider now owns 100,151 shares of the company’s stock, valued at approximately $4,877,353.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,302 shares of company stock valued at $2,875,861. Company insiders own 2.20% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in IMPV. North Run Capital LP boosted its stake in Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock valued at $30,788,000 after buying an additional 681,772 shares during the period. Clearbridge Investments LLC boosted its stake in Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock valued at $51,826,000 after buying an additional 403,809 shares during the period. BNP Paribas Arbitrage SA boosted its stake in Imperva by 8,392.3% in the first quarter. BNP Paribas Arbitrage SA now owns 200,927 shares of the software maker’s stock valued at $8,248,000 after buying an additional 198,561 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new stake in Imperva during the first quarter valued at $7,192,000. Finally, Bank of Nova Scotia acquired a new stake in Imperva during the first quarter valued at $7,184,000. Institutional investors and hedge funds own 92.72% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/07/21/zacks-analysts-anticipate-imperva-inc-impv-will-post-quarterly-sales-of-74-29-million.html.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.